Population-Level HPV Vaccine Impact Among Girls with HIV in South Africa

A report on research published in The Lancet Global Health described a population-level HPV vaccine evaluation in South Africa, including reductions in vaccine-type HPV infections after implementation of a national, school-based program. It also described protection as being observed among adolescent girls and young women with and without HIV in a high HIV-prevalence setting.

The report described South Africa’s free, school-based national HPV vaccination program as introduced in 2014 and offered through public schools. Eligibility in the description was tied to school grade and age: the program offered vaccination to Grade 4 girls aged nine years and older attending public schools across the country. Delivery was positioned as school-based and national in scope, with the target group defined by enrollment in a specific grade within the public school system. In the report’s description, the program was a nationwide, public-school–delivered offer of HPV vaccination to age-eligible Grade 4 girls.

The report highlighted a consistent outcome pattern centered on infection with HPV types included in the vaccine. Investigators were described as having observed “substantial reductions in vaccine-type HPV infections,” and the narrative characterized the vaccine as providing “excellent protection.” Impact was described as having been assessed in adolescent girls and young women with and without HIV, with protection reported among girls living with HIV as well as those without HIV. The reductions in vaccine-type infection described in the report were presented as spanning groups defined by HIV status.

The report quoted investigators as framing early delivery through a national public program as demonstrating protection in a high HIV-prevalence context and as being linked to reduced future cervical cancer risk, including among girls living with HIV. The same reporting relayed an author framing that these findings carry broader relevance for countries with high HIV prevalence, presented as “major global implications." Taken together, the report separated observed reductions in vaccine-type infection from broader statements about cervical cancer risk reduction and global relevance.

Key Takeaways:

• The report described population-level reductions in vaccine-type HPV infections following implementation of a national, school-based HPV vaccination program in South Africa.
• Protection was reported among adolescent girls and young women living with HIV as well as among those without HIV.
• Authors framed early, school-based delivery in a high HIV-prevalence setting as relevant to future cervical cancer risk reduction.